MOTS-c vs Amycretin

MOTS-c and Amycretin are both investigational peptides with applications in metabolic health, yet they diverge sharply in origin, mechanism, and evidence strength. MOTS-c, a mitochondrial-derived peptide discovered in 2015, acts as an endogenous metabolic regulator with anti-aging and exercise-mimetic properties in preclinical models. Amycretin, developed by Novo Nordisk, is a synthetic unimolecular co-agonist of GLP-1 and amylin receptors, designed for oral obesity treatment with robust clinical data. This comparison highlights their distinct research niches: MOTS-c offers insights into mitochondrial signaling and aging, while Amycretin provides a clinically validated model for dual-receptor agonism in weight management.

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene (MT-RNR1), first characterized by Lee et al. at USC. Its primary mechanism involves AMPK activation, which enhances glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. In mouse models, MOTS-c prevented diet-induced obesity and insulin resistance, and aged mice treated with MOTS-c ran twice as long on treadmill tests, suggesting exercise-mimetic effects. A modified analog, CB4211, demonstrated good tolerability in a Phase 1 trial, but no clinical studies of native MOTS-c in humans have been completed. Thus, the evidence base remains preclinical, with key claims centered on improving insulin sensitivity, glucose metabolism, and anti-obesity effects through mitochondrial regulation.

Amycretin is a first-in-class unimolecular peptide co-agonist that simultaneously activates GLP-1 and amylin receptors, developed by Novo Nordisk as an oral tablet for obesity. Its dual mechanism leverages synergistic effects: GLP-1 agonism slows gastric emptying and promotes satiety, while amylin agonism reduces food intake and glucagon secretion. In the Phase 2 REDEFINE 1 trial, oral amycretin achieved up to 13.1% body weight loss at 36 weeks, a notable result for an oral peptide. Unlike small-molecule oral GLP-1 agonists (e.g., orforglipron), amycretin retains peptide structure and dual-target engagement. Phase 3 trials are expected in 2026. Key claims include significant weight loss via oral administration, synergistic dual-receptor action, and a subcutaneous formulation showing similar efficacy.

Both peptides are investigated for metabolic health, but their research contexts differ markedly. MOTS-c is primarily studied in preclinical models for anti-aging, exercise enhancement, and age-related metabolic decline, reflecting its mitochondrial origin. Amycretin is exclusively researched for weight loss and obesity treatment, with clinical trials demonstrating robust efficacy. While both target metabolic pathways, MOTS-c offers a window into mitochondrial signaling and longevity, whereas Amycretin provides a clinically validated model for dual-receptor agonism in energy balance regulation. Researchers should consider these distinct applications when selecting a peptide for specific metabolic or aging studies.

MOTS-c has shown no adverse effects in preclinical animal studies, but its safety in humans remains unknown due to the absence of completed clinical trials for the native peptide. The modified analog CB4211 was well tolerated in a Phase 1 trial, offering limited safety data. For Amycretin, the most common adverse events are gastrointestinal—nausea, vomiting, and diarrhea—consistent with GLP-1 agonist class effects. These are typically mild to moderate, occurring during dose escalation and diminishing with continued treatment. A Phase 1 trial (Gasiorek et al., Lancet 2025) reported generally good tolerability across dose ranges. Researchers must weigh the unknown human safety profile of MOTS-c against the well-characterized but manageable GI side effects of Amycretin.